This article was originally published in The Tan Sheet
Manasquan, N.J.-based firm, formerly known as Cytodyne Technologies, estimates its debt at between $50 mil. and $100 mil. and assets at $10 mil. to $50 mil. in Oct. 16 Chapter 11 filing. Filing puts federal and state lawsuits related to Cytodyne's ephedra-containing and ephedra-free Xenadrine products, including a hold on wrongful death suit filed by widow of Orioles pitcher Steve Bechler (1"The Tan Sheet" July 21, 2003, p. 3). Cytodyne President Robert Chinery formed Nutraquest in June when Cytodyne licensed rights to all its products to Xenadrine manufacturer Phoenix Labs (2"The Tan Sheet" June 23, 2003, p. 13)...
You may also be interested in...
Cytodyne's failure to adequately warn consumers about potential risks from taking ephedra-containing Xenadrine RFA-1 is the basis for a wrongful-death lawsuit filed by Orioles pitcher Steve Bechler's widow, Kiley Bechler, July 16
Cytodyne Technologies has licensed the distribution, marketing and sales rights to its products to Apex Fitness Group's Phoenix Labs division, the firms announced June 16
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.